A new small-molecule inhibitor of the autophagy-initiating kinase ULK1 serves to block a critical survival mechanism activated upon inhibition of mTORC1, potentially enhancing treatment efficacy for mTOR inhibitors currently in clinical trials for cancer treatment.
References
Abada, A. & Elazar, Z. EMBO Rep. 15, 839–852 (2014).
Galluzzi, L. et al. EMBO J. 34, 856–880 (2015).
Rubinsztein, D.C., Codogno, P. & Levine, B. Nat. Rev. Drug Discov. 11, 709–730 (2012).
Dowdle, W.E. et al. Nat. Cell Biol. 16, 1069–1079 (2014).
Bago, R. et al. Biochem. J. 463, 413–427 (2014).
Ronan, B. et al. Nat. Chem. Biol. 10, 1013–1019 (2014).
Egan, D.F. et al. Mol. Cell 59, 285–297 (2015).
Papinski, D. et al. Mol. Cell 53, 471–483 (2014).
Petherick, K.J. et al. J. Biol. Chem. 290, 11376–11383 (2015).
Kim, J. et al. Nat. Cell Biol. 13, 132–141 (2011).
Yao, J.C. et al. N. Engl. J. Med. 364, 514–523 (2011).
Mathew, R. et al. Cell 137, 1062–1075 (2009).
Wei, H., Wang, C., Croce, C.M. & Guan, J.L. Genes Dev. 28, 1204–1216 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Goodwin, J., Murphy, L. bULKing up mTOR inhibition. Nat Chem Biol 11, 758–760 (2015). https://doi.org/10.1038/nchembio.1909
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1909
- Springer Nature America, Inc.